Quick Answer
TREACE MEDICAL CONCEPTS, INC. reported Operating Income Loss of -$54.15 million for the year ending 2025.
- TREACE MEDICAL CONCEPTS, INC. showed an increase of +2.8% in Operating Income Loss from 2024 to 2025.
- This data is from TREACE MEDICAL CONCEPTS, INC.'s annual report (Form 10-K), filed with the SEC on February 27, 2026.
- XBRL data for this metric is available from 2019 to 2025 (7 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2020: -$1.20 million | Q2 2020: -$1.52 million | Q3 2020: -$63.0 thousand | Q1 2021: -$1.40 million | Q2 2021: -$4.05 million | Q3 2021: -$5.46 million | Q1 2022: -$8.10 million | Q2 2022: -$11.93 million | Q3 2022: -$11.32 million | Q1 2023: -$13.78 million | Q2 2023: -$13.05 million | Q3 2023: -$17.82 million | Q1 2024: -$18.97 million | Q2 2024: -$21.38 million | Q3 2024: -$15.13 million | Q1 2025: -$15.58 million | Q2 2025: -$16.97 million | Q3 2025: -$15.68 million.
- Over the full 7 years of available data (2019 to 2025), TREACE MEDICAL CONCEPTS, INC.'s Operating Income Loss has declined by 1,431.9%.
- Historical annual values: Fiscal year 2025: -$54.15 million | Fiscal year 2024: -$55.69 million | Fiscal year 2023: -$51.43 million | Fiscal year 2022: -$34.84 million | Fiscal year 2021: -$16.51 million | Fiscal year 2020: $855.0 thousand | Fiscal year 2019: -$3.54 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: